Endocrine Abstracts

Background: Craniopharyngioma is a rare epithelial tumor of the central nervous system, affecting both children and adults and associated with significant morbidity.Objective: To study the posttreatment evolution of craniopharyngioma in children and adults in a large mixed cohort.Material and Methods: We performed a retrospective review of craniopharyngioma patients evaluated in the National Institute of Endocrinology in Bucharest ...

Background: Craniopharyngioma is a rare epithelial tumor of the central nervous system, affecting both children and adults and associated with significant morbidity.Objective: To study the potential differences in the clinical and radiological presentation of craniopharyngioma in children versus adults in a large mixed cohort.Material and methods: We performed a retrospective review of craniopharyngioma patients evaluated in the Na...

In acromegaly, treatment with somatostatin analogs (SSA) normalizes growth hormone (GH) and insulin-like growth factor 1 (IGF1) secretion in about half of the patients. Usually, the disease relapses biochemically within few months after treatment withdrawal.We present two acromegalic patients, women of 49 and 53 years at diagnosis, respectively, who achieved stable remission of the disease after medical treatment withdrawal. One had a microadenoma, the o...

Objective: Patients with pituitary macroadenomas and concomitant hypopituitarism have a reduced life expectancy due to various comorbidities.Aim: To investigate mortality in patients with non-functioning pituitary adenomas (NFAs) and independent prognostic factors influencing survival.Design: Retrospective cohort study in a tertiary neuroendocrine university department.Methods: A total of 364 patients (177F/1...

Acromegaly control/remission is defined by stringent criteria: normal age-/sex-adjusted IGF1 and random GH (GHr) <1 ng/ml or a GH nadir (GHn) during oral glucose tolerance test (OGTT) of <0.4 ng/ml. However discordances between GH and IGF1 have been recorded in about 30% of patients. We retrospectively analyzed the evolution in patients with acromegaly and discordant GH–IGF1 levels while being treated with somatostatin analogs (SSA) and/or cabergoline (CAB).<p...

Introduction: Adrenal carcinomas are rare tumor. It has an estimated incidence of ~0.5–2 new cases per million people per year. Just 25% of adults with hormone-secreting adrenal carcinomas present overproduction of both glucocorticoids and androgens. Women develop adrenal carcinomas more often than men.Objectives: We report a case of 47-year-old female presented with weight gain, generalized weakness and hypertension for the last 6 months. Phy...

Introduction: New-onset hyperandrogenism is rare in postmenopausal women and is usually associated with causes such as ovarian hyperthecosis, androgen-secreting tumor or medication. Patients with hyperandrogenism and breast cancer need a special attention when choosing the treatment.Case history: A 46-year old woman diagnosed with hormone receptor-positive breast cancer at 37 years old, for which she underwent surgery, chemotherapy, radiotherapy and horm...

10% of patients with adrenal tumours have bilateral lesion.Objective: To evaluate clinical, imagistic and hormonal characteristics of bilateral adrenal tumours.Design and mehods: Retrospective series of 150 consecutive patients (104F, 46M) with bilateral adrenal tumours with maximal diameter of at least 1 cm, evaluated from 2001 to 2015 in a tertiary endocrinology clinic with clinical, hormonal and imagistic methods.<p class="a...

Background and Aims: GH receptor antagonist (Pegvisomant –PEG) has been shown to obtain IGF1 normalization in 60–90% of patients with acromegaly in clinical trials. The aim of the study is to evaluate real life response and side effects of PEG treatment in monotherapy versus combined with somatostatin analogues and/or cabergoline in patients with somatostatin analogues resistant acromegaly.Methods: We included 40 patients (22F/18 M) cons...

Background and aims: Patients with GH secreting or nonfunctioning pituitary adenoma (NFPA) have high mortality ratios, despite enhancement of the old therapies. The aim of the study is to analyze the relationship between mortality and risk factors, including therapy, in patients with acromegaly (ACM) and NFPA evaluated in the last 16 years.Methods: We evaluated retrospectively 749 patients with pituitary adenoma (435F/314M), 386 with ACM and 363 with NFP...